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Abstract
Objectives. To examine SLEDAI-2000 cut-off scores for definition of active SLE and to determine the
sensitivity to change of SLEDAI-2000 for the assessment of SLE disease activity and minimal clinically
meaningful changes in score.
Methods. Data from two multi-centre studies were used in the analysis: in a cross-sectional and a lon-
gitudinal fashion. At every assessment, data were collected on SLEDAI-2000 and treatment. The
cross-sectional analysis with receiver operating characteristic (ROC) curves was used to examine the
appropriate SLEDAI-2000 score to define active disease and increase in therapy was the reference stand-
ard. In the longitudinal analysis, sensitivity to change of SLEDAI-2000 was assessed with multinomial
logistic regression. ROC curves analysis was used to examine possible cut-points in score changes
associated with change in therapy, and mean changes were estimated.
Results. In the cross-sectional analysis, the most appropriate cut-off scores for active disease were 3 or
4. In the longitudinal analysis, the best model for predicting treatment increase was with the change in
SLEDAI-2000 score and the score from the previous visit as continuous variables. The use of cut-points
was less predictive of treatment change than the use of continuous score. The mean difference in the
change in SLEDAI-2000 scores, adjusted for prior score, between patients with treatment increase and
those without was 2.64 (95% CI 2.16, 3.14).
Conclusions. An appropriate SLEDAI-2000 score to define active disease is 3 or 4. SLEDAI-2000 index is
sensitive to change. The use of SLEDAI-2000 as a continuous outcome is recommended for comparative
purposes.
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The SLEDAI index is a global score index developed for
the assessment of SLE disease activity [1]. The index has
been shown to be reliable, has construct validity and is
sensitive to change [211]. However, the index focused on
new or recurrent manifestations and failed to capture
on-going activity, which led to a revision (SLEDAI-2000
index) [12].
SLEDAI-2000 has not been formally validated for as-
sessment of SLE disease activity. It has been shown to
correlate well with the original SLEDAI, which is to be ex-
pected as SLEDAI-2000 is derived from SLEDAI and the
majority of the items are identical. Appropriate definitions
of active disease based on the score have not been
clearly established. This is an important issue as cut-off
scores are used in studies to stratify patients and to de-
termine eligibility. Three studies have suggested a cut-off
score of 4 or 6 for the original SLEDAI [1315]. However,
these studies were hampered by small sample size, use of
abstracted case histories or the use of physician’s global
assessment as gold standard for disease activity, which
was not ideal as it had unsatisfactory performance and
poor agreement between expert physicians, particularly
in patients with manifestations in multiple systems [5, 8,
11, 16, 17]. Furthermore, minimal clinically meaningful
changes in the score for SLEDAI-2000 have not been es-
tablished. These may be relevant in studies either to clas-
sify whether the patient’s disease activity over time has
improved, worsened or remained unchanged, or on a
mean basis to be used for sample size calculations. A
few studies have tried to address the former issue but
again were limited by small numbers [10], use of simple
descriptive statistics for analysis [14], use of abstracted
case histories [16] or employing physician’s global as-
sessment as the gold standard [10, 14, 16, 18]. As a
result, the minimal increase in SLEDAI score associated
with worsening of disease activity from these studies
ranges from 3 to 8. This could lead to inconsistencies
with classification of response and difficulties in the inter-
pretation/analysis of results.
We have used data from two large multi-centre studies
to address the following:
(i) to examine SLEDAI-2000 cut-off scores that could
define active SLE;
(ii) to determine if SLEDAI-2000 is sensitive to change;
and
(iii) to consider the minimal clinically meaningful
changes in SLEDAI-2000 score at individual level
and population level.
Patients and methods
Data were available from two multi-centre studies in the
UK. Both studies were designed primarily for the valid-
ation of the BILAG-2004 index and have been described
in detail previously [19, 20]. All patients met the revised
ACR criteria for classification of SLE [21, 22]. Patients
were excluded if they were pregnant, under the age of
18 years or unable to give valid consent. Both studies
received ethical approval from Hull and East Riding
Research Ethics Committee, and were carried out in ac-
cordance with the Helsinki Declaration. Written consent
was obtained from all patients. The majority of patients
were involved in both studies that ran concurrently. It
should be noted that treatment of the patient was based
on physician’s clinical judgement, and not on the
BILAG-2004 index or SLEDAI-2000 scores (which were
not available to the physician when the treatment decision
was made).
Cross-sectional analysis
This analysis was used to examine SLEDAI-2000 cut-off
scores to define active disease. The data came from a
study that commenced in March 2005 and was completed
in August 2006. At every assessment, data (SLEDAI-2000
and treatment) were collected. This study is longitudinal in
design as the majority of patients had repeated assess-
ments. However, the analysis was cross-sectional in
nature at the time of the assessment and statistical meth-
ods are used to allow for multiple assessments from the
same patient (see below).
Change in therapy was used as the reference standard
for disease activity. This was the change in therapy follow-
ing the assessment and a robust definition was used as
described previously [19] (see supplementary data avail-
able at Rheumatology Online). For this analysis, change
in therapy was categorized into increase in therapy and
no increase in therapy.
Longitudinal analysis
A longitudinal study was used to examine the sensitivity to
change for SLEDAI-2000. This study commenced in
March 2005 and was completed in April 2007. Patients
were followed up prospectively and data (SLEDAI-2000
index and treatment) were collected for all consecutive
visits/encounters the patients had with their physicians.
This is conceptually different from the cross-sectional
analysis above as the changes in disease activity and
treatment between two consecutive visits are analysed
in a longitudinal fashion. Therefore, each observation for
the analysis was derived from two consecutive visits.
Change in therapy between consecutive visits was used
as the external reference for change in disease activity.
Change in therapy was the change in treatment between
two consecutive visits. The definition for change in ther-
apy (supplementary data are available at Rheumatology
Online) was similar to the one used in the cross-sectional
study and had been described [20]. Three categories of
changes in therapy were defined: no change, increase in
therapy and decrease in therapy. All statistical analyses
were performed using Stata for Windows version 8 (Stata
Corporation, College Station, TX, USA).
Cross-sectional statistical analysis
A receiver operating characteristic (ROC) curve was used
to derive information on appropriate cut-off scores for
active disease associated with increase in therapy [23].
www.rheumatology.oxfordjournals.org 983
Definition of active disease and clinically meaningful change with SLEDAI-2000Logistic regression was used to estimate the sensitivity,
specificity, positive predictive value (PPV) and negative
predictive value (NPV) associated with various SLEDAI-
2000 cut-off scores. Robust variance estimation was
used in the analysis as this is a commonly used statistical
method that accounts for multiple assessments from the
same patient [24]. Increase in therapy was the outcome
variable, and the classification of active disease according
to SLEDAI-2000 score using various cut-off scores were
the explanatory variables for the PPV and NPV estimates,
and vice-versa for the sensitivity and specificity calcula-
tions. The Youden index (sensitivity+specificity1) was
used to compare alternative cut-off scores [25]. This index
is a measure of overall diagnostic effectiveness. It ranges
between 0 and 1, with values close to 1 indicating very
good diagnostic effectiveness and values near 0 indicat-
ing poor effectiveness.
Longitudinal statistical analysis
The sensitivity to change of the index was assessed using
the external responsiveness method [26]. The extent to
which changes in SLEDAI-2000 score between two con-
secutive visits relate to the corresponding changes in
therapy (external reference) was studied. This analysis
was performed using multinomial logistic regression
(with robust variance estimation) with change in therapy
as the three-level outcome variable and change in
SLEDAI-2000 score and SLEDAI-2000 score of the previ-
ous visit as potential explanatory variables. Where appro-
priate, fractional polynomials were used to examine the
best fitting function (powers) of the continuous variables
(such as change in SLEDAI-2000 score and the
SLEDAI-2000 score of the previous visit), which predict
the outcome variables [27].
In addition, analyses were done using increase in ther-
apy vs no increase in therapy as a binary outcome variable
to generate ROC curves related to possible cut-off points,
at individual level, for increases and decreases in SLEDAI-
2000 score associated with increase in therapy and no
increase in therapy, respectively. Estimated population-
averaged changes were derived from linear regression
analyses with change in SLEDAI-2000 score as the
outcome variable.
In a model for change in treatment with two binary
explanatory variables defining specified increase and
decrease in SLEDAI-2000 score, the baseline comparator
for change in score was minimal change in score (defined
as neither specified increase nor decrease in score had
been observed), while the baseline comparator for change
in treatment was no change in therapy. The results were
reported in odds ratio (OR) or coefficient with 95% CI.
Results
Cross-sectional analysis
There were 369 patients who contributed 1510 assess-
ments and the demographics are summarized in
Table 1. Increase in therapy occurred in 22.6% of assess-
ments, while in 21.2% there was reduction in therapy and
no change in treatment occurred in 56.2%. The mean
(S.D.) SLEDAI-2000 score was 2.9 (3.4) with a range from
0 to 26.
ROC curves analysis for SLEDAI-2000 score as a pre-
dictor of increase in therapy is summarized in Table 2. The
most appropriate cut-off scores for active disease
appears to be 3 or 4, as both have similar performance
characteristics and the best Youden index values. The
performance of using the cut-off scores of 3 or 4 (ROC
area under the curve 0.71) is comparable with that of
using the total score as a continuous variable (ROC area
under the curve 0.76) in predicting treatment increase.
Longitudinal analysis
There were 1761 assessments from 347 SLE patients that
contributed 1414 observations for analysis (demographics
are summarized in Table 1). There was an increase in
treatment in 22.7% of observations, whereas 37.3% had
therapy decreased, and, in 40.0%, there was no change in
treatment. An increase in score occurred in 344 observa-
tions (mean increase 3.5, range 122), whereas there was
a decrease in score in 409 observations (mean decrease
3.8, range 114).
The increase in SLEDAI-2000 score was significantly
associated with treatment increase (OR 1.24, 95% CI
1.18, 1.32) and inversely associated with treatment reduc-
tion (OR 0.93, 95% CI 0.90, 0.97). When the SLEDAI-2000
score of the previous visit was also included in the regres-
sion model, both the change in score and the previous
visit score were significantly associated with increase in
therapy (Table 3). Hence, the model with just change
in score was insufficient to explain change in therapy
(particularly increase in therapy).
ROC curves analysis of cut-off points for change in
SLEDAI-2000 score as predictors of increase in therapy
is summarized in Table 4. High Youden index value was
not achieved. The highest values were associated with
minimal cut-points for increase in scores of 1 and 2.
However, for the best performance in predicting increase
in therapy, an increase in score of at least 3 or 4 would be
TABLE 1 Demographics of recruited patients
Patient characteristics
Cross sectional
analysis
(n=369)
Longitudinal
analysis
(n=347)
Female sex, % 92.7 92.9
Age, mean (S.D.), years 41.6 (13.2) 40.9 (12.9)
Race, %
Caucasian 59.9 57.9
Afro-Caribbean 18.4 20.5
South Asian 18.4 19.0
Oriental 1.4 1.2
Others 1.9 1.4
Disease duration,
mean (S.D.), years
8.8 (7.7) 8.2 (7.8)
Number of assessments,
median (range)
4( 1 11) 4 (218)
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cut-points of 1 or 2. There was, however, a compromise in
the sensitivity.
ROC curves analysis was also performed to examine
the minimal decrease in score that was associated with
no increase in therapy (combination of decrease in ther-
apy and no change in therapy) as summarized in Table 5.
Very low Youden index values were achieved with the
best values corresponding to the use of minimal decrease
in score of 1 or 2. The results were similar when the
analysis with decrease in therapy was used instead of
no increase in treatment (data not shown). Interestingly,
high PPVs could be achieved for the prediction of no in-
crease in therapy, whereas it was high NPVs that were
achieved for the prediction of an increase in therapy.
Combining the findings of the above analyses on
cut-points for change in SLEDAI-2000 score in a multi-
nomial logistic regression analysis (with minimal clinically
meaningful change in score defined as an increase of
53 for worsening and decrease of 51 for improvement),
worsening of score was significantly associated with
increase in therapy, whereas improvement in score was
associated with treatment reduction (Table 6). However,
there was a significant association between worsening
of the score and decrease in treatment as well. The results
were similar with minimum increase in score of 4 or
minimum decrease in score of 2 (data not shown).
Several models of change in SLEDAI-2000 score were
examined and compared (data not shown). The model with
change in score as a continuous variable and the score of
the previous visit included, had the best performance
in explaining increase in therapy as compared with any
model based on cut-off points. This relationship between
increase in therapy with change in score and the score of
theprevious visit (both ascontinuousvariables) wasfurther
examined using multivariable fractional polynomial regres-
sion. This analysis confirmed that the best fitting model
for increase in therapy is the one with a linear function
(power of 1) of change in SLEDAI-2000 score and the
SLEDAI-2000 score of the previous visit.
The estimated mean change in score associated with
treatment increase was 1.49 (95% CI 1.06, 1.92), whereas
the mean decrease associated with no increase in therapy
was 0.76 (95% CI 0.92, 0.60). The resultant difference,
2.25 (95% CI 1.70, 2.80), might be taken as the minimal
clinically important difference for clinical trial design.
However, a strong dependence of change in SLEDAI-
2000 score on the score at the previous visit was found
(P<0.001). With adjustment for prior score, the estimated
mean difference in the change in scores for patients with
a treatment increase vs those without was 2.64 (95% CI
2.16, 3.14). This represents the effect associated with
treatment increase compared with patients with no treat-
ment increase and comparable prior scores. Moreover,
the estimated residual variance associated with change
in SLEDAI-2000 score after the adjustment for prior
score is 6.64, whereas it is 9.94 without adjustment.
Thus, a trial with the adjusted difference in change in
SLEDAI-2000 score as the primary outcome would require
a sample size approximately one-half that of a trial that
aimed to demonstrate an unadjusted effect [(6.64/(2.64)
2)/
(9.94/(2.25)
2)=0.49].
Discussion
We have undertaken a comprehensive assessment of
SLEDAI-2000 index with regards to definition of active
disease, minimal clinically meaningful change in score
and sensitivity to change of the index. These have
involved large sample sizes in routine practice and the
TABLE 2 ROC curves analysis of SLEDAI-2000 index as a predictor of increase in therapy
Cut-off
score
Sensitivity
% (95% CI)
Specificity
% (95% CI) PPV % (95% CI) NPV % (95% CI)
Youden
index
2 87.7 (83.2, 91.1) 43.0 (38.5, 47.6) 31.1 (27.9, 34.4) 92.3 (89.5, 94.3) 0.30
3 71.9 (65.8, 77.3) 70.7 (66.1, 75.0) 41.8 (37.5, 46.3) 89.6 (87.2, 91.6) 0.42
4 70.8 (64.6, 76.3) 72.2 (67.5, 76.4) 42.7 (38.2, 47.2) 89.3 (87.0, 91.4) 0.42
5 44.4 (38.0, 51.1) 87.5 (84.3, 90.1) 51.0 (45.0, 57.0) 84.3 (81.9, 86.5) 0.32
6 42.1 (35.9, 48.6) 88.1 (84.9, 90.7) 50.9 (44.7, 57.0) 83.9 (81.4, 86.0) 0.30
7 28.4 (22.4, 35.1) 93.3 (90.7, 95.2) 55.4 (48.0, 62.6) 81.6 (79.0, 84.0) 0.22
8 26.3 (20.6, 32.9) 93.8 (91.2, 95.7) 55.6 (47.6, 63.2) 81.3 (78.7, 83.6) 0.22
9 17.3 (13.1, 22.4) 96.7 (95.1, 97.9) 60.8 (52.0, 69.0) 80.0 (77.4, 82.3) 0.14
10 17.3 (13.1, 22.4) 97.0 (95.3, 98.1) 62.8 (53.5, 71.1) 80.0 (77.5, 82.3) 0.14
TABLE 3 Association between change in therapy with
change in SLEDAI-2000 score and SLEDAI-2000 score of
the previous visit
SLEDAI-2000
Variables
Increase
in therapy
OR
a (95% CI)
Decrease
in therapy
OR
a (95% CI)
Change in
SLEDAI-2000 score
1.37 (1.28, 1.46) 0.93 (0.87, 0.99)
Previous visit
SLEDAI-2000 score
1.24 (1.17, 1.31) 1.0 (0.9, 1.1)
aPer unit change in SLEDAI-2000 score.
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and longitudinal perspectives.
This is the first study to assess the sensitivity to change
of SLEDAI-2000, since it was revised from the SLEDAI
index. Using the robust external responsiveness method,
the results confirmed that SLEDAI-2000 index was sensi-
tive to change as the changes in the score correlated well
with the corresponding change in therapy. This result is
consistent with previous studies on sensitivity to change
of SLEDAI [711].
Our analysis demonstrated that the most appropriate
SLEDAI-2000 cut-off score for definition of active disease
linked to the need to increase therapy was 3 or 4. This was
consistent with the results from our reliability study [15]
and another study by Gladman et al. [14]. However, this is
different from the cut-off score of 6 suggested by
Abrahamowicz et al. [13]. This is most likely due to the
difference in the study design. Our study was prospective
and derived from a large number of patients within clinical
practice, whereas the Abrahamowicz study was based
on hypothetical situations derived from 30 abstracted
case histories. As such, the result of our study is more
applicable to clinical practice.
The longitudinal analysis to determine the minimal clin-
ically meaningful changes in SLEDAI-2000 score (based
on the need for treatment) showed that, in general, the
performance of cut-points at individual level was not at-
tractive. Although a minimal clinically meaningful increase
in score of 1 or 2 provided the best results for sensitivity
and specificity, a higher threshold for increase in score of
TABLE 5 ROC curves analysis of SLEDAI-2000 index to determine the most appropriate minimal decrease in score
associated with no increase in therapy
Decrease in
SLEDAI-2000
score (magnitude)
Sensitivity
% (95% CI)
Specificity
% (95% CI) PPV % (95% CI) NPV % (95% CI)
Youden
index
51 31.7 (28.9, 34.6) 80.7 (76.3, 84.4) 84.8 (81.1, 87.9) 25.7 (22.8, 29.0) 0.12
52 30.2 (27.5, 33.2) 81.9 (77.6, 85.6) 85.1 (81.2, 88.3) 25.7 (22.7, 28.8) 0.12
53 16.0 (13.8, 18.5) 91.6 (88.1, 94.1) 86.6 (81.4, 90.6) 24.3 (21.6, 27.1) 0.08
54 14.9 (12.7, 17.4) 93.1 (90.0, 95.4) 88.1 (82.8, 91.9) 24.3 (21.7, 27.2) 0.08
55 7.2 (5.7, 9.2) 96.6 (94.1, 98.0) 87.8 (80.1, 92.8) 23.4 (20.9, 26.1) 0.04
56 7.0 (5.5, 9.0) 97.2 (94.8, 98.5) 89.5 (81.8, 94.2) 23.5 (21.0, 26.2) 0.04
57 4.7 (3.4, 6.4) 98.1 (96.0, 99.1) 89.5 (79.7, 94.8) 23.2 (20.8, 25.8) 0.03
TABLE 4 ROC curves analysis of SLEDAI-2000 index to determine the most appropriate minimal increase in score
associated with increase in therapy
Increase in
SLEDAI-2000
score (magnitude)
Sensitivity
% (95% CI)
Specificity
% (95% CI) PPV % (95% CI) NPV % (95% CI)
Youden
index, %
51 47.4 (41.6, 53.2) 82.4 (80.0, 84.6) 44.2 (39.0, 49.5) 84.2 (81.6, 86.5) 0.30
52 44.9 (39.3, 50.5) 84.4 (82.2, 86.3) 45.7 (40.4, 51.2) 83.9 (81.4, 86.2) 0.29
53 28.7 (23.7, 34.2) 95.4 (94.0, 96.5) 64.8 (56.8, 72.0) 82.0 (79.5, 84.3) 0.24
54 26.2 (21.4, 31.6) 95.9 (94.5, 96.9) 65.1 (56.5, 72.8) 81.6 (79.1, 83.8) 0.22
55 14.6 (10.6, 19.9) 98.4 (97.4, 99.1) 73.4 (60.8, 83.1) 79.7 (77.1, 82.0) 0.13
56 13.7 (9.7, 19.0) 98.8 (97.9, 99.3) 77.2 (64.5, 86.3) 79.6 (77.0, 81.9) 0.13
57 9.0 (6.0, 13.3) 99.5 (98.7, 99.8) 85.3 (67.7, 94.1) 78.8 (76.3, 81.2) 0.09
TABLE 6 Sensitivity to change analysis of SLEDAI-2000 index with minimal increase in score of 3 to indicate worsening
and minimal decrease in score of 1 to indicate improvement (n=1414)
Change in
SLEDAI-2000 score
Number of
observations
Increase in
therapy
OR (95% CI)
Decrease in
therapy
OR (95% CI)
Minimal change 863 1.00 1.00
Increase 53 142 10.57 (6.20, 18.01) 1.89 (1.03, 3.47)
Decrease 51 409 1.05 (0.74, 1.49) 1.97 (1.51, 2.56)
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diction of increase in therapy (due to its superior PPV), but
with a resultant decrease in the sensitivity. This is similar
to the results of two previous studies with SLEDAI index
[14, 18]. However, Liang et al. [16] suggested a higher
cut-off (increase in score of 58 for flare and decrease in
score of 56 for improvement). This discrepancy could be
due to the fact that Liang et al. involved lupus experts
reviewing abstracted case histories, whereas this study
is based on clinical practice.
Our data suggest a minimal clinically meaningful
decrease in score of 1 or 2, which is much smaller in mag-
nitude than that used in the SLE Responder Index (SRI)
(decrease in score of 54) [28]. Although SRI uses
Safety of Estrogens in Lupus Erythematosus National
Assessment (SELENA)-SLEDAI [29] instead of
SLEDAI-2000, both the indices are almost identical
and would be expected to have similar performance.
The SELENA-SLEDAI cut-off point for the SRI was
based on previous work by Gladman et al. [14] using
the original SLEDAI, not through the analysis of the
belimumab trial data. In the analysis of the belimumab
trial data, there were significantly more patients with
improvement in score of 1 or 2 in the belimumab
group than in the placebo group, but there was no sig-
nificant difference between the groups when the im-
provement in score of 54 was used. This is
consistent with our findings and suggests that a lower
threshold for improvement in SELENA-SLEDAI score
might be considered for the SRI. However, it is accept-
able to select a higher threshold that would require the
drug to have bigger treatment effect as compared with
placebo. For a higher threshold to be used, it would be
desirable to have a higher SELENA-SLEDAI score of >4
(instead of 54) at study entry to allow the drug to
achieve the required treatment effect (decrease in
score of 54).
More importantly, our results indicate that the use of a
single cut-off for change in SLEDAI-2000 score will sacri-
fice information and performance. In addition, change in
SLEDAI-2000 score on its own is inadequate in explaining
change in therapy. The score from which it has changed
from is equally important. This is not surprising as the
score from the previous assessment puts the change in
score into context; for example, a change from a score
of 18 to 15 may not constitute significant change as the
patient continues to have very active disease, whereas a
change of similar magnitude from 6 to 3 would indicate
improvement in disease activity.
We did assess several alternative models of change in
score in the analysis (data not shown), but, nevertheless,
the best model to explain change in therapy is with the
score of the previous visit and the change in score (as a
continuous variable) included. Although the minimal
clinically meaningful change at individual level is desirable
for definition of response in clinical studies, our analysis
highlights the drawback of using such cut-off points with
change in score. Therefore, it has to be emphasized that
SLEDAI-2000 score is designed as a continuous variable
and performs best as such. The use of cut-off points
will lead to loss of information and compromise its
performance.
Further analysis revealed that the estimated population
average difference in change in SLEDAI-2000 score be-
tween patients requiring an increase in therapy and those
without treatment increase is 2.6, after adjustment for
prior SLEDAI-2000 score. This difference could be recom-
mended as a basis for defining minimal clinically important
treatment effects for clinical studies.
We have not performed specific analysis with regards to
the effect of differential system involvement on the cut-off
values. This is because SLEDAI-2000 index was designed
and intended to be used as a global score index.
Furthermore, it is not uncommon for SLE disease activity
to affect a few systems concomitantly (such as pleurisy
with rash and arthritis). It is less common for disease ac-
tivity to affect only one single system and the numbers
would be too small to make meaningful interpretation.
We would not recommend using global score index
(such as SLEDAI-2000) as the primary outcome end-point
for clinical trials assessing the differential effects of ther-
apy on different systems: a system-based index would be
more appropriate.
Rheumatology key messages
. An appropriate SLEDAI-2000 score to define active
SLE disease is 3 or 4.
. SLEDAI-2000 is best used as a continuous score in
longitudinal analysis.
. The use of cut-off points with SLEDAI-2000 in lon-
gitudinal analysis will compromise its performance.
Acknowledgements
We would like to thank the nurse specialists of all partici-
pating centres, Dr Madelynn Chan, the Wellcome Trust
Clinical Research Facility (Birmingham), Lupus UK,
Manchester Academic Health Sciences Centre,
Manchester NIHR Biomedical Research Centre and
Arthritis Research Campaign for their support.
Funding: This study was supported by a grant from
Arthritis Research Campaign (grant no. 16081). Funding
to pay the Open Access publication charges for this article
was provided by Arthritis Research UK.
Disclosure statement: C.-S.Y. has received consultancy
payments from Roche Pharmaceuticals, Genentech and
Teva Pharmaceuticals. He had previously been funded by
an unrestricted educational grant from Vifor Pharma/
Aspreva. Pharmaceuticals. C.G. has received consultancy
payments and honoraria from Roche Pharmaceuticals,
Merck Serono, Genentech, Amgen, Bristol Myers Squibb
and Vifor Pharma/Aspreva Pharmaceuticals. All other
authors have declared no conflicts of interest.
www.rheumatology.oxfordjournals.org 987
Definition of active disease and clinically meaningful change with SLEDAI-2000Supplementary data
Supplementary data are available at Rheumatology
Online.
References
1 Bombardier C, Gladman DD, Urowitz MB, Caron D,
Chang CH. Derivation of the SLEDAI. A disease activity
index for lupus patients. The Committee on Prognosis
Studies in SLE. Arthritis Rheum 1992;35:63040.
2 Hawker G, Gabriel S, Bombardier C, Goldsmith C,
Caron D, Gladman D. A reliability study of SLEDAI: a
disease activity index for systemic lupus erythematosus.
J Rheumatol 1993;20:65760.
3 Guzman J, Cardiel MH, Arce-Salinas A, Sanchez-
Guerrero J, Alarcon-Segovia D. Measurement of disease
activity in systemic lupus erythematosus. Prospective
validation of 3 clinical indices. J Rheumatol 1992;19:
15518.
4 Petri M, Hellmann D, Hochberg M. Validity and reliability
of lupus activity measures in the routine clinic setting.
J Rheumatol 1992;19:539.
5 Gladman DD, Goldsmith CH, Urowitz MB et al.
Crosscultural validation and reliability of 3 disease activity
indices in systemic lupus erythematosus. J Rheumatol
1992;19:60811.
6 Liang MH, Socher SA, Larson MG, Schur PH. Reliability
and validity of six systems for the clinical assessment of
disease activity in systemic lupus erythematosus. Arthritis
Rheum 1989;32:110718.
7 Ward MM, Marx AS, Barry NN. Comparison of the validity
and sensitivity to change of 5 activity indices in systemic
lupus erythematosus. J Rheumatol 2000;27:66470.
8 Gladman DD, Goldsmith CH, Urowitz MB et al. Sensitivity
to change of 3 systemic lupus erythematosus disease
activity indices: international validation. J Rheumatol 1994;
21:146871.
9 Chang E, Abrahamowicz M, Ferland D, Fortin PR.
Comparison of the responsiveness of lupus disease
activity measures to changes in systemic lupus
erythematosus activity relevant to patients and physicians.
J Clin Epidemiol 2002;55:48897.
10 Fortin PR, Abrahamowicz M, Clarke AE et al. Do lupus
disease activity measures detect clinically important
change? J Rheumatol 2000;27:14218.
11 Brunner HI, Feldman BM, Bombardier C, Silverman ED.
Sensitivity of the systemic lupus erythematosus disease
activity index, british isles lupus assessment group index,
and systemic lupus activity measure in the evaluation
of clinical change in childhood-onset systemic lupus
erythematosus. Arthritis Rheum 1999;42:135460.
12 Gladman DD, Ibanez D, Urowitz MB. Systemic lupus
erythematosus disease activity index 2000. J Rheumatol
2002;29:28891.
13 Abrahamowicz M, Fortin PR, Du BR, Nayak V, Neville C,
Liang MH. The relationship between disease activity and
expert physician’s decision to start major treatment in
active systemic lupus erythematosus: a decision aid for
development of entry criteria for clinical trials. J Rheumatol
1998;25:27784.
14 Gladman DD, Urowitz MB, Kagal A, Hallett D. Accurately
describing changes in disease activity in Systemic Lupus
Erythematosus. J Rheumatol 2000;27:3779.
15 Yee CS, Isenberg DA, Prabu A et al. BILAG-2004
index captures systemic lupus erythematosus disease
activity better than SLEDAI-2000. Ann Rheum Dis 2008;
67:8736.
16 Liang M, Fortin P, Schneider M et al. The American
College of Rheumatology response criteria for systemic
lupus erythematosus clinical trials: measures of overall
disease activity. Arthritis Rheum 2004;50:341826.
17 Wollaston SJ, Farewell VT, Isenberg DA et al. Defining
response in systemic lupus erythematosus: a study by the
Systemic Lupus International Collaborating Clinics group.
J Rheumatol 2004;31:23904.
18 Petri M, Genovese M, Engle E, Hochberg M et al.
Definition, incidence, and clinical description of flare in
systemic lupus erythematosus. A prospective cohort
study. Arthritis Rheum 1991;34:93744.
19 Yee CS, Farewell V, Isenberg DA et al. British Isles Lupus
Assessment Group 2004 index is valid for assessment of
disease activity in systemic lupus erythematosus. Arthritis
Rheum 2007;56:41139.
20 Yee CS, Farewell V, Isenberg DA et al. The BILAG-2004
index is sensitive to change for assessment of SLE
disease activity. Rheumatology 2009;48:6915.
21 Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria
for the classification of systemic lupus erythematosus.
Arthritis Rheum 1982;25:12717.
22 Hochberg MC. Updating the American College of
Rheumatology revised criteria for the classification of
systemic lupus erythematosus. Arthritis Rheum 1997;40:
1725.
23 Zweig MH, Campbell G. Receiver-operating characteristic
(ROC) plots: a fundamental evaluation tool in clinical
medicine. Clin Chem 1993;39:56177.
24 Williams RL. A note on robust variance estimation for
cluster-correlated data. Biometrics 2000;56:6456.
25 Schisterman EF, Perkins NJ, Liu A, Bondell H. Optimal
cut-point and its corresponding Youden Index to dis-
criminate individuals using pooled blood samples.
Epidemiology 2005;16:7381.
26 Husted JA, Cook RJ, Farewell VT, Gladman DD.
Methods for assessing responsiveness: a critical re-
view and recommendations. J Clin Epidemiol 2000;53:
45968.
27 Royston P, Altman DG. Regression using fractional
polynomials of continuous covariates: parsimonious
parametric modelling (with discussion). App Stat 1994;43:
42967.
28 Furie RA, Petri MA, Wallace DJ et al. Novel
evidence-based systemic lupus erythematosus responder
index. Arthritis Rheum 2009;61:114351.
29 Petri M, Kim MY, Kalunian KC et al. Combined oral
contraceptives in women with systemic lupus
erythematosus. N Engl J Med 2005;353:25508.
988 www.rheumatology.oxfordjournals.org
Chee-Seng Yee et al.